Specialty Pharmacy

Questions still persist regarding immunologic mechanisms of MS treatments and vitamin D.

Side effects, familial support and liver condition among factors that influence hepatitis C treatment decisions.

Initiative does not prohibit the purchase or sale of private coverage duplicating the public plan.

The FDA has accepted for review Amgen's new drug application for etelcalcetide to treat secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis.

Pharmacy interventions for patients taking new medications can improve adherence, reduce health care costs, and improve outcomes.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the development of medical marijuana within the specialty space.

HCV drug combination may cut treatment time by 75%.

Baricitinib improved disease activity in patients not responding to conventional or biologic DMARDs.

Combination of Cotellic and Zelboraf shows superior overall and progression free survival in melanoma treatment.

Newly discovered pathway may prove effective target for treatment of triple-negative breast cancer.

Direct-acting antivirals may help eradicate hepatitis C virus in patients who recently had a liver transplant, reducing the need for further transplants.

Biosimilar may offer patients with RA drug cost relief in the near future.

Genetic information may help develop treatment guidelines for Crohn's disease and ulcerative colitis.

Patients with diabetes fare better after surgery when pharmacists manage their high blood sugar.

Micro RNA based blood test may be used with imaging features to accurately predict disease severity.

Once-a-week treatment is the first oral proteasome inhibitor to reach late stage clinical development.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses the alignment between specialty pharmacies and ACOs.

Benefits of Plavix found to outweigh potential adverse events.

Rectal microbicide formulated as an enema may inhibit the spread of HIV and other sexually transmitted infections.

Combination of sofosbuvir and simeprevir may have an unexpected side effect in HCV therapy.

Roflumilast has been found to help prevent flare-ups associated with COPD.

Experimental DMARD may be clinically beneficial for active rheumatoid arthritis treatment.

HIV-1-associated neurocognitive disorders afflict almost half of all patients with HIV.

The Institute for Safe Medication Practices (ISMP) is alerting pharmacists about the risks of mixing up idarucizumab (Praxbind) with idarubicin.

Serum levels may determine impact of anti-tumor necrosis factor drugs.

Recent news in cancer drug development.